Literature DB >> 15901128

Overexpression of CD10 and reduced MUC2 expression correlate with the development and progression of colorectal neoplasms.

Tsuyoshi Iwase1, Ryoji Kushima, Ken-ichi Mukaisho, Shoji Mitsufuji, Takeshi Okanoue, Takanori Hattori.   

Abstract

There are two opposing theories of the natural history of colorectal neoplasm, adenoma-carcinoma sequence and de novo carcinogenesis. To elucidate the histogenesis of colorectal carcinoma, we investigated the expression of CD10, MUC2, MUC5AC, MUC6, and p53 in colorectal neoplasms. Sixty-seven morphologically distinct neoplastic specimens were divided into the following groups according to morphology: adenoma (groups A and B), protruded-type carcinoma (group C), superficial-type carcinoma with adenomatous component (group D), or superficial-type carcinomas without any adenomatous component (group E). Diagnoses of adenomas and carcinomas were based upon the Vienna classification of gastrointestinal epithelial neoplasia. The expression of CD10 in group E lesions was more intense than in the other groups. Regardless of morphology, MUC2 expression was significantly decreased in CD10-positive carcinomas, and the p53-positive rate was much higher in CD10-positive than in CD10-negative carcinomas. The overexpression of CD10 and reduced expression of MUC2 may be associated with the development and progression of colorectal carcinoma. A specific tendency was evident in superficial-type carcinomas without any adenomatous component (de novo carcinomas). These carcinomas are considered to be more aggressive than other morphologically distinct carcinomas.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15901128     DOI: 10.1016/j.prp.2004.09.016

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  10 in total

1.  Mucinous phenotype and CD10 expression of primary adenocarcinoma of the small intestine.

Authors:  Reiko Kumagai; Kenichi Kohashi; Shunsuke Takahashi; Hidetaka Yamamoto; Minako Hirahashi; Kenichi Taguchi; Kenichi Nishiyama; Yoshinao Oda
Journal:  World J Gastroenterol       Date:  2015-03-07       Impact factor: 5.742

2.  Modifier-concept of colorectal carcinogenesis: lipidomics as a technical tool in pathway analysis.

Authors:  Nikolaus Gassler; Christina Klaus; Elke Kaemmerer; Andrea Reinartz
Journal:  World J Gastroenterol       Date:  2010-04-21       Impact factor: 5.742

3.  Multi-institutional study of risk factors of liver metastasis from colorectal cancer: correlation with CD10 expression.

Authors:  Shin Fujita; Hirokazu Taniguchi; Takashi Yao; Tadakazu Shimoda; Hideki Ueno; Takashi Hirai; Masayuki Ohue
Journal:  Int J Colorectal Dis       Date:  2010-03-05       Impact factor: 2.571

4.  Clinicopathological Significance of Mucin 2 Immuno-histochemical Expression in Colorectal Cancer: A Meta-Analysis.

Authors:  Li Li; Pei-Lin Huang; Xiao-Jin Yu; Xiao-Dong Bu
Journal:  Chin J Cancer Res       Date:  2012-09       Impact factor: 5.087

5.  Transmembrane mucin MUC1 overexpression and its association with CD10⁺ myeloid cells, transforming growth factor-β1 expression, and tumor budding grade in colorectal cancer.

Authors:  Do Trong Khanh; Eiji Mekata; Ken-ichi Mukaisho; Hiroyuki Sugihara; Tomoharu Shimizu; Hisanori Shiomi; Satoshi Murata; Shigeyuki Naka; Hiroshi Yamamoto; Yoshihiro Endo; Tohru Tani
Journal:  Cancer Sci       Date:  2013-05-21       Impact factor: 6.716

Review 6.  Cell surface markers in colorectal cancer prognosis.

Authors:  Larissa Belov; Jerry Zhou; Richard I Christopherson
Journal:  Int J Mol Sci       Date:  2010-12-28       Impact factor: 5.923

7.  Clinical relevance of neutral endopeptidase (NEP/CD10) in melanoma.

Authors:  Elsa F Velazquez; Molly Yancovitz; Anna Pavlick; Russell Berman; Richard Shapiro; Dusan Bogunovic; David O'Neill; Yi-Lo Yu; Joanna Spira; Paul J Christos; Xi Kathy Zhou; Madhu Mazumdar; David M Nanus; Leonard Liebes; Nina Bhardwaj; David Polsky; Iman Osman
Journal:  J Transl Med       Date:  2007-01-05       Impact factor: 5.531

8.  Assessing CD 10 Expression Level and Its Prognostic Impact in Egyptian Patients with Urothelial Carcinoma.

Authors:  Marwa T Hussien; Eatemad Helmy; Tarek M Elsaba; Azza Elkady; Hani Alrefai; Helal F Hetta
Journal:  Asian Pac J Cancer Prev       Date:  2020-06-01

9.  Expression Profiling of Proliferation and Apoptotic Markers along the Adenoma-Carcinoma Sequence in Familial Adenomatous Polyposis Patients.

Authors:  Jayson Wang; Nabil El-Masry; Ian Talbot; Ian Tomlinson; Malcolm R Alison; Mona El-Bahrawy
Journal:  Gastroenterol Res Pract       Date:  2013-02-13       Impact factor: 2.260

Review 10.  Role of B Cell Development Marker CD10 in Cancer Progression and Prognosis.

Authors:  Deepshikha Mishra; Sunita Singh; Gopeshwar Narayan
Journal:  Mol Biol Int       Date:  2016-11-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.